+

WO2003052069A3 - Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation - Google Patents

Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation Download PDF

Info

Publication number
WO2003052069A3
WO2003052069A3 PCT/US2002/039867 US0239867W WO03052069A3 WO 2003052069 A3 WO2003052069 A3 WO 2003052069A3 US 0239867 W US0239867 W US 0239867W WO 03052069 A3 WO03052069 A3 WO 03052069A3
Authority
WO
WIPO (PCT)
Prior art keywords
apaf
flj1115
pathway
methods
modifier
Prior art date
Application number
PCT/US2002/039867
Other languages
English (en)
Other versions
WO2003052069A2 (fr
Inventor
Tak Hung
Michael Costa
Monique Nicoll
Roel P Funke
Danxi Li
Original Assignee
Exelixis Inc
Tak Hung
Michael Costa
Monique Nicoll
Roel P Funke
Danxi Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Tak Hung, Michael Costa, Monique Nicoll, Roel P Funke, Danxi Li filed Critical Exelixis Inc
Priority to AU2002360586A priority Critical patent/AU2002360586A1/en
Publication of WO2003052069A2 publication Critical patent/WO2003052069A2/fr
Publication of WO2003052069A3 publication Critical patent/WO2003052069A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Selon cette invention, on identifie des gènes humains FLJ1115 comme modulateurs du mécanisme d'action d'Apaf-1, ces gènes étant, par conséquent, des cibles thérapeutiques pour des troubles associés à la fonction défectueuse d'Apaf-1. L'invention porte sur des procédés d'identification des modulateurs de l'Apaf-1, ces procédés consistant à cribler des agents qui modulent l'activité de FLJ1115.
PCT/US2002/039867 2001-12-13 2002-12-12 Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation WO2003052069A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002360586A AU2002360586A1 (en) 2001-12-13 2002-12-12 FLJ1115 AS MODIFIER OF THE Apaf-1 PATHWAY AND METHODS OF USE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34031301P 2001-12-13 2001-12-13
US60/340,313 2001-12-13
US35744702P 2002-02-15 2002-02-15
US60/357,447 2002-02-15

Publications (2)

Publication Number Publication Date
WO2003052069A2 WO2003052069A2 (fr) 2003-06-26
WO2003052069A3 true WO2003052069A3 (fr) 2004-01-29

Family

ID=26992055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039867 WO2003052069A2 (fr) 2001-12-13 2002-12-12 Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation

Country Status (2)

Country Link
AU (1) AU2002360586A1 (fr)
WO (1) WO2003052069A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065937A2 (fr) * 1998-06-16 1999-12-23 Thomas Jefferson University Apaf-1 tronquee et ses procedes d'utilisation
US6228603B1 (en) * 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
US6291643B1 (en) * 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228603B1 (en) * 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
US6291643B1 (en) * 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
WO1999065937A2 (fr) * 1998-06-16 1999-12-23 Thomas Jefferson University Apaf-1 tronquee et ses procedes d'utilisation

Also Published As

Publication number Publication date
AU2002360586A1 (en) 2003-06-30
AU2002360586A8 (en) 2003-06-30
WO2003052069A2 (fr) 2003-06-26

Similar Documents

Publication Publication Date Title
WO2002099059A3 (fr) Genes u5-200kd en tant que modificateurs de la voie p53 et procedes d'utilisation associes
WO2002099074A3 (fr) Slc7s utilises en tant que modificateurs de la voie p53 et procedes d'utilisation correspondants
WO2003014301A3 (fr) Hprp4 en tant que modificateurs de la voie de passage p53 leurs et methodes d'utilisation
WO2002098889A3 (fr) Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation
WO2003035833A3 (fr) Modificateurs de la voie de passage de p53 et leurs procedes d'utilisation
WO2003051905A3 (fr) Taojik utilises en tant que modificateurs de la voie beta-catenine et procedes d'utilisation associes
WO2002099043A8 (fr) P5crs identifies comme des modificateurs de la voie p53 et procedes d'utilisation
WO2003035831A3 (fr) Lrrcaps en tant que modificateurs de la voie de passage p53 et leurs procedes d'utilisation
WO2003052069A3 (fr) Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation
WO2003052068A3 (fr) Genes mbcat agissant comme modificateurs du mecanisme d'action de la beta-catenine et methodes d'utilisation
WO2004061086A3 (fr) Flj10607 utilise en tant que modificateur de la voie de l'axine et procedes d'utilisation correspondants
WO2003052066A3 (fr) Klcs utilises en tant que genes modificateurs de la voie p53 et procedes d'utilisation correspondant
WO2004024881A3 (fr) Ldlr utilise en tant que modificateur de la voie p53 et procedes d'utilisation associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载